The new app allows for fully accredited multimedia CME content such as treatment updates, conference highlights, and tests.
Author: Global Cancer Consortium
The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories’ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.
CombinatoRx has signed an all-stock merger agreement with Neuromed.
Aureon Laboratories, a developer of predictive tests for cancer care, has been featured in a cable television segment produced by the Yonkers Chamber of Commerce.
Clarient has filed a registration statement with the Securities and Exchange Commission on Form S-3 relating to shares of Clarient owned by Safeguard.
A new genetic discovery could lead to easier detection of colorectal cancer.
Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.